Business Context and Reporting Period
This Form 6-K filing by Alterity Therapeutics Limited, a development stage enterprise, covers the month of December 2023. The report was filed on December 11, 2023, and incorporates by reference into various Registration Statements on Forms S-8 and F-3.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, this specific report focuses on corporate governance matters rather than financial performance data.
Material Changes
The primary material event disclosed is the submission of Exhibit 99.1, titled "Grant of Waiver & Addendum - EGM 29 December 2023," indicating an upcoming Extraordinary General Meeting and associated corporate actions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management commentary on future outlook, specific risks, contingencies, or unusual items beyond the procedural notice of the EGM.
Investor Verification Checklist
- Verify the specific terms of the "Grant of Waiver & Addendum" referenced in Exhibit 99.1.
- Confirm the agenda and voting outcomes of the Extraordinary General Meeting scheduled for December 29, 2023.
- Review the referenced Registration Statements (Forms S-8 and F-3) for details on capital structure and share offerings.